Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPresident Donald Trump sparked surprise by posting a video Sunday that endorsed Medicare coverage of CBD —the legal cannabidiol substance derived from the cannabis plant and widely marketed as beneficial for health.
The video, produced by a Trump associate’s organization with CBD business ties, jolted the cannabis industry, sending stocks soaring Monday and raising hopes that the president will take a permissive approach to marijuana. But it also drew concerns from some researchers who say that CBD’s much hyped health benefits, while tantalizing, largely remain unproven.
Trump’s post could boost the CBD industry, which took off in 2018 when Congress legalized hemp, the nonintoxicating version of the cannabis plant from which CBD is derived. CBD is often marketed as a calming supplement, appearing in gummies, creams, oils, drinks and even pet treats as part of the broader wellness industry.
But the industry has recently stalled and now faces Republican efforts to restrict hemp products in a way business groups say would effectively end legal CBD sales. Even though hemp isn’t supposed to get people high, it has come under scrutiny as states grapple with a flood of intoxicating gummies, chocolates and drinks synthesized from the plant.
Jonathan S. Miller, general counsel for the trade group U.S. Hemp Roundtable, called Trump’s video post a “seminal moment” for the industry. “President Trump stepped into this discussion and—in his unique way—made a real strong statement that hemp-derived CBD is an extremely valuable resource for Americans,” Miller said.
The video shared by Trump called hemp-derived CBD a “game changer,” suggesting it could help “restore” the body’s endocannabinoid system and ease pain, improve sleep and reduce stress for older Americans. “And 20 percent of seniors are already using CBD today for pain, arthritis, cancer, symptoms, sleep disorders, Alzheimer’s and many other ailments of aging,” the video said. “Older adults are suffering needlessly. Hemp-derived CBD can help them feel better, live longer and improve their quality of life significantly.”
The Food and Drug Administration has approved only one CBD medication, which is used to treat a severe form of childhood epilepsy. Use for treating any other conditions is “way ahead of the science, and let alone Medicare coverage for it,” said Meg Haney, director of the Cannabis Research Laboratory at Columbia University Department of Psychiatry. “In terms of evidence, all we have is this childhood epilepsy and nothing else.”
The video Trump shared was produced by The Commonwealth Project, founded by Howard Kessler, a Palm Beach, Florida billionaire. Past media accounts noted that Kessler and his wife attended Trump’s 2005 wedding and often dined at Mar-a-Lago, Trump’s private club in Palm Beach.
The project’s website describes Kessler as an entrepreneur who has “spent the past five years devoting himself to exploring how medical cannabis can revolutionize senior healthcare” and says funding comes from a Kessler company that trademarked a brand of CBD gummies targeted at senior citizens.
A representative of the project and the White House did not return requests for comment.
The Department of Health and Human Services, which oversees the agency that handles Medicare, declined to comment.
Michael Bronstein, the president of the American Trade Association of Cannabis and Hemp, said in a statement that the group supports Medicare coverage for CBD products, and Trump’s video highlights the therapeutic potential of CBD.
“For too long, CBD products have been unfairly grouped in with intoxicating hemp products,” he said.
Kevin Sabet, who leads an organization opposed to marijuana legalization, said he believes the cannabis industry is “grasping at straws” to paint Trump’s video as a signal of larger reform. “If the past is any indication, usually these posts have very little to nothing to do with formal policy positions,” said Sabet, president of Smart Approaches to Marijuana.
Trump has pleased the cannabis industry before when he signaled support for a stalled Biden-era proposal to loosen federal restrictions on marijuana, a move that could boost profits for industry.
Researchers caution that evidence of CBD’s benefits are far from conclusive.
Early research appears promising in using CBD to treat opioid cravings, said Yasmin Hurd, an addiction researcher at the Icahn School of Medicine at Mount Sinai, who is leading those studies. But she said there is little data on what doses of CBD would work—if any—for seniors grappling with inflammation, chronic pain or other conditions.
Doctors are also trying to figure out how CBD interacts with prescription drugs. Those combinations might reduce the effect—or increase the risk—of those drugs, said Ziva D. Cooper, director of the University of California at Los Angeles Center for Cannabis and Cannabinoids.
“This can be a significant issue, especially for the elderly who are taking many medications,” Cooper said. “Even though so many people are using CBD, we still have a lot to learn.”
Researchers have also raised alarms over CBD products with misleading labeling or that contain unknown chemicals. In 2023, the FDA said it needed Congress to create a new regulatory system to oversee potentially risky CBD products. Last summer, FDA researchers published findings that suggest the risk of liver damage in people who take unregulated CBD products.
Haney, of Columbia University, this year published a small study that showed patients given CBD for neuropathic pain reported less pain—as did those who received a placebo. She said other studies have had similar results, illustrating the power of patient expectations when taking CBD products.
“When you don’t have placebo control, of, course, everyone feels better,” Haney said.
Please enable JavaScript to view this content.
Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.